In a landmark collaboration, Eli Lilly and Company (India) has partnered with the Association of Physicians of India (API) to launch ‘Obesity Gurukul’, a nationwide educational initiative aimed at empowering healthcare professionals to better manage and treat obesity. The announcement comes amid rising concerns over India’s dual burden of obesity and type 2 diabetes, which affects over 180 million people across the country.
About Obesity Gurukul
-
The program will serve as a clinical education platform for physicians, diabetologists, and endocrinologists.
-
It focuses on evidence-based approaches, patient-centric care, and latest treatment modalities, including GLP-1 receptor agonists like tirzepatide, marketed by Eli Lilly as Mounjaro.
-
Gurukul sessions will be held in major cities and tier-2 towns, with support from leading medical institutions and experts.
Why It Matters
-
India is projected to have 400 million obese individuals by 2050, according to The Lancet.
-
Obesity is linked to over 200 health complications, including cardiovascular disease, sleep apnea, and certain cancers.
-
Despite the scale of the problem, clinical obesity management remains under-addressed, especially in primary care settings.
Leadership Commentary
“Obesity Gurukul is our commitment to bridging the knowledge gap in metabolic health. We aim to equip physicians with the tools to deliver holistic and effective obesity care,” said Winselow Tucker, President & GM, Eli Lilly India.
Strategic Context
-
The initiative complements Eli Lilly’s recent launch of Mounjaro (tirzepatide) in India, a once-weekly injectable therapy for chronic weight management and type 2 diabetes.
-
The company is also working with HDFC Bank and exploring partnerships with government bodies to expand access to obesity treatments.
Sources: IndiaMedToday, Business Today, Elets eHealth